Japanese
Title転移性骨腫瘍に伴う骨性疼痛に対する放射性ストロンチウム (89Sr) 製剤SMS.2Pの第II相臨床試験
Subtitle技術報告
Authors木村良子*, 濱本研*, 鈴木謙三**, 横山邦彦***, 久田欣一***, 笠木寛治****, 小西淳二****, 一矢有一*****, 増田康治*****, 久保敦司§, 鳥塚莞爾#
Authors(kana)
Organization*愛媛大学医学部放射線科, **東京都立駒込病院放射線科, ***金沢大学医学部核医学科, ****京都大学医学部核医学科, *****九州大学医学部放射線科, §慶應義塾大学医学部放射線科, #福井医科大学
Journal核医学
Volume32
Number3
Page311-321
Year/Month1995/3
Article報告
Publisher日本核医学会
Abstract「要旨」疼痛を有する前立腺癌骨転移患者9例を対象に, 塩化ストロンチウム (89Sr) 注射液 (SMS.2P) の第II相臨床試験を行った. 本剤は, 投与後大部分は血漿中に存在し, 速やかに消失した. 尿中排泄率は, 患者により個人差がみられた. 投与後, 問題となる重篤な副作用はみられず, 全例, 臨床上の安全性に問題はなかった. 投与後2〜4日に4例で一時的な痛みの増強が, またそのうち2例で悪心・嘔吐がみられたが, いずれも治癒あるいは軽快した. 血液学的検査値の変動については, いくつか異常変動がみられた. 特に, 血小板数の減少は89Srの放射線による骨髄抑制の影響も考えられた. 腫瘍マーカーの変動については, 本剤に起因するものかあるいは病態を反映したものか判定は困難であった. 投与後1〜2週間で効果が発現してから少なくとも8週間まで鎮痛効果が持続し, 全例で鎮痛剤として有効であった. 痛みの改善に伴い, 生活の質も改善がみられた.
Practice臨床医学：一般
KeywordsStrontium-89, Pain palliation, Bone metastases, Prostate cancer
English
TitlePhase II Clinical Trial of the Radioactive Strontium (89Sr) Chloride Agent, SMS.2P for Pain Palliation in Patients with Prostate Cancer with Bone Metastases
Subtitle
AuthorsYoshiko KIMURA*, Ken HAMAMOTO*, Kenzo SUZUKI**, Kunihiko YOKOYAMA***, Kinichi HISADA***, Kanji KASAGI****, Junji KONISHI****, Yuichi ISHIYA*****, Kouji MASUDA*****, Atsushi KUBO§, Kanji TORIZUKA#
Authors(kana)
Organization*Department of Radiology, Ehime University School of Medicine, **Department of Radiology, Tokyo Metropolitan Komagome Hospital, ***Department of Nuclear Medicine, Kanazawa University School of Medicine, ****Department of Nuclear Medicine, Kyoto University School of Medicine, *****Department of Radiology, Kyushu University School of Medicine, §Department of Radiology, Keio University School of Medicine, #Fukui Medical School
JournalThe Japanese Journal of nuclear medicine
Volume32
Number3
Page311-321
Year/Month1995/3
ArticleReport
PublisherTHE JAPANESE SOCIETY OF NUCLEAR MEDICINE
Abstract[Summary] The phase II clinical trial of a strontium (89Sr) chloride agent (SMS.2P) was performed in 9 patients with painful bone metastases secondary to prostate cancer. After an intravenous administration, 89Sr circulated in the plasma and was rapidly cleared. Urinary excretion varied widely among the patients. No serious acute side effects were observed. A mild transient increase in pain was reported by 4 patients 2-4 days after administration, two of whom complained of mild nausea or vomiting. All symptoms improved and never became a clinical problem. There were some abnormal hematological parameters. In particular, a decrease in the platelet level seemed to be a marrow suppression due to 89Sr irradiation. It is difficult to discriminate between the effects of 89Sr and the progress of the disease using tumor markers. The pain level improved within 2 weeks after administration and the effect continued for at least 8 weeks, which improved the quality of life for these patients.
PracticeClinical medicine
KeywordsStrontium-89, Pain palliation, Bone metastases, Prostate cancer

【全文PDF】